| Literature DB >> 35845851 |
Heba Samir Elama1, Shereen M Shalan1, Yasser El-Shabrawy1, Manal I Eid1, Abdallah M Zeid1.
Abstract
A facile, accurate, eco-friendly and sensitive spectrofluorometric method was evolved to assay alfuzosin hydrochloride (AFH) and tadalafil (TDF) in different matrices. Such a co-administered combination is clinically used for the treatment of lower urinary tract symptoms. Both compounds are characterized by their native fluorescence spectra upon excitation at specific wavelengths. Their characteristic fluorescence spectra were used for sensitive assay of the studied analytes in tablets and human biological samples. The assay principle is based on first-order synchronous spectrofluorometric scan using Δλ = 60 nm in which AFH peaks were recorded at 366 nm. Meanwhile, TDF measurements were recorded at 293 nm in the same scans without overlap with AFH spectra. Recent analytical chemistry trends were implemented to lessen occupational and environmental perils, using ethanol as a diluting solvent for method optimization and application. Linearity ranges were 5.0-90.0 and 10.0-100.0 ng ml-1 for AFH and TDF, respectively in their raw materials with average % recoveries of 100.44% and 99.73% in raw materials, 100.15% and 100.20% in spiked plasma, and 97.14% and 99.99% in spiked urine. The proposed method was successfully applied to Prostetrol and Starkoprex commercial tablets with no interference with common tablet additives.Entities:
Keywords: alfuzosin; biological samples; lower urinary tract symptoms; spectrofluorometry; tadalafil
Year: 2022 PMID: 35845851 PMCID: PMC9277242 DOI: 10.1098/rsos.220330
Source DB: PubMed Journal: R Soc Open Sci ISSN: 2054-5703 Impact factor: 3.653
Figure 1Chemical structures of alfuzosin hydrochloride and tadalafil.
Obtained data for the proposed spectrofluorometric method. Sb, SD of the slope; Sa, s.d. of the intercept; Sy/x, s.d. of the residuals.
| parameter | AFH | TDF |
|---|---|---|
| concentration range (ng ml−1) | 5–90 | 10–100 |
| LOD (ng ml−1) | 0.72 | 1.52 |
| LOQ (ng ml−1) | 2.18 | 4.61 |
| correlation coefficient ( | 0.9999 | 0.9999 |
| intercept | 1.26 | 0.08 |
| slope | −0.5 | −0.20 |
| 0.17 | 0.12 | |
| 0.11 | 0.09 | |
| 0.002 | 0.001 | |
| % error | 0.47 | 0.59 |
| % RSD | 1.23 | 1.32 |
| mean found (%) | 100.44 | 99.73 |
| ±standard deviation (s.d.) | 1.24 | 1.32 |
Method application to raw materials and synthetic mixtures of AFH and TDF compared with their comparison methods.
| raw materials | ||||||
|---|---|---|---|---|---|---|
| proposed method | comparison methods [ | |||||
| amount taken (ng ml−1) | % founda | amount taken (ng ml−1) | % founda | % founda | ||
| compound | AFH | TDF | AFH | TDF | ||
| 5 | 102.16 | 10 | 98.13 | 101.71 | 98.27 | |
| 10 | 100.95 | 20 | 100.67 | 99.44 | 100.24 | |
| 20 | 101.28 | 40 | 98.82 | 99.50 | 101.42 | |
| 40 | 98.23 | 60 | 101.36 | 100.24 | 99.25 | |
| 60 | 100.42 | 100 | 99.66 | |||
| 80 | 99.94 | — | — | |||
| 90 | 100.12 | — | — | |||
| Student- | 0.29 (2.26) | 0.07 (2.45) | ||||
| 1.37 (8.94) | 1.05 (5.95) | |||||
| synthetic mixtures | ||||||
| amount taken (ng ml−1) | % founda | |||||
| compound | AFH | TDF | AFH | TDF | ||
| 10 | 20 | 100.23 | 98.08 | |||
| 20 | 40 | 99.75 | 98.60 | |||
| 60 | 60 | 99.29 | 99.15 | |||
| mean ± s.d. | 99.76 ± 0.47 | 98.60 ± 0.54 | ||||
| s.e. | 0.27 | 0.31 | ||||
aEach result is an average value of three separate determinations.
Method application to Prostetrol® and Starkoprex® commercial tablets of the studied drugs.
| parameter | proposed method | comparison methods [ | |
|---|---|---|---|
| amount taken (ng ml−1) | % founda | % founda | |
| Prostetrol (alfuzosin, 10 mg tab−1) | 10 | 101.29 | 100.53 |
| 20 | 101.81 | 98.40 | |
| 40 | 98.02 | 101.26 | |
| 80 | 100.36 | 99.60 | |
| no. of trials | 4 | 4 | |
| mean ± s.d. | 100.37 ± 1.68 | ||
| Student- | 0.40 (2.47)b | ||
| 1.85 (9.28)b | |||
| Starkoprex (tadalafil, 5 mg tab−1) | 20 | 98.27 | 98.29 |
| 50 | 101.00 | 99.14 | |
| 80 | 100.17 | 101.71 | |
| 100 | 99.71 | — | |
| no. trials | 4 | 3 | |
| mean ± s.d. | 99.79 ± 1.15 | 99.71 ± 1.78 | |
| Student- | 0.06 (3.18)b | ||
| 2.42 (9.55)b | |||
aEach result is an average value of three separate determinations.
bThe values in brackets refer to tabulated t and F tests' values.
Method application to spiked human plasma and urine samples.
| parameter | plasma samples | urine samples | ||||||
|---|---|---|---|---|---|---|---|---|
| amount taken (ng ml−1) | % recovery | amount taken (ng ml−1) | % recovery | |||||
| AFH | TDF | AFH | TDF | AFH | TDF | AFH | TDF | |
| mixture | 10 | 10 | 106.93 | 99.24 | 10 | 10 | 83.69 | 100.79 |
| 30 | 30 | 86.35 | 106.1 | 20 | 30 | 105.19 | 97.58 | |
| 50 | 50 | 106.66 | 99.13 | 60 | 70 | 97.54 | 102.85 | |
| 70 | 70 | 102.66 | 93.96 | 80 | 100 | 102.12 | 98.72 | |
| 90 | 100 | 98.16 | 102.58 | |||||
| mean | 100.15 | 100.20 | 97.14 | 99.99 | ||||
| ± s.d.a | 8.50 | 4.50 | 9.50 | 2.33 | ||||
| slope | −0.26 | −0.07 | 3.88 | 1.27 | ||||
| intercept | −0.25 | −1.25 | −0.53 | 166.89 | ||||
| 0.90 | 0.19 | 5.23 | 4.34 | |||||
| 0.78 | 0.09 | 3.42 | 2.96 | |||||
| 0.01 | 0.002 | 0.09 | 0.06 | |||||
aAverage of three separate estimations.
Figure 2Emission spectra of (a–f). TDF; 10, 20, 40, 50, 80 and 100 ng ml−1, (g): AFH; 6 ng ml−1 and (h); blank ethanol. All measurements were performed at an excitation wavelength of 250 nm.
Figure 3Superimposed first derivative integrals of synchronous fluorescence spectra Δλ of 60 of: (a) AFH (60 ng ml−1), (b) TDF (60 ng ml−1) and (c) a synthetic mixture of both drugs at the same concentration (60 ng ml−1).
Comparison between the proposed method and a side of previous reports. NS: not stated. ACN: acetonitrile. UV: ultraviolet.
| parameter | proposed method | reported methods | |||||
|---|---|---|---|---|---|---|---|
| AFH | |||||||
| linear range (ng ml−1) | 5–90 | [ | [ | [ | [ | [ | [ |
| LOD (ng ml−1) | 0.72 | 0.78 | 50 | 682 | NS | 1.60 | 1.59 |
| LOQ (ng ml−1) | 2.18 | 0.039 | 150 | 12 500 | NS | 4.86 | 11.76 |
| applied technique | 1st-order synchronous spectrofluorometry | RP-HPLC fluorometric detection | HPLC-UV | reaction with ninhydin UV at 575 nm | diazotization with nitrous acid UV at 520 nm | native Fluorescence | derivatization with ortho-phthalaldehyde, spectrofluorometry |
| selectivity | method tolerance was discussed | AFH resolved from plasma | AFH resolved from degradation products | NS | NS | selective | reagent reacts with NH2 |
| application | tablets, plasma and urine | plasma | tablets | tablets | tablets | tablets | human plasma |
| main drawback | use ACN | tR = 10.7 min; utilize ACN | tedious derivatization; high LOD | tedious derivatization; high LOD | high LOQ | derivatization costs time | |
| TDF | proposed method | reported methods | |||||
| linear range (ng ml−1) | 10–100 | [ | [ | [ | [ | [ | [ |
| LOD (ng ml−1) | 0.57 | 980 | NS | 30 | 5.76 | 1 | 0.24 |
| LOQ (ng ml−1) | 1.72 | 2960 | NS | 90 | 17.09 | 4 | 0.70 |
| applied technique | 1st-order synchronous spectrofluorometry | HPLC- UV at 260 nm | HPLC- UV at 285 nm | coupling with gold nanoparticles UV at 660 nm | coupling with gold nanoparticles spectrofluorometry | native fluorescence | native fluorescence |
| selectivity | method tolerance was discussed | separation of TDF from ambrisentan and their degradation products | NS | common tablet excipients did not interfere to a certain drug concentration | no interference from tablet excipients | selective | |
| application | tablets, plasma and urine | tablets | tablets | tablet | tablet and spiked plasma | tablet and spiked plasma | spiked human plasma |
| main drawback | tR 7.10 min m; ph CH3OH and ACN 60% | ACN 50% | stand 5.0 min before measurement | ACN diluting solvents | solvent 0.1 M methanolic H2SO4 | ||
Figure 4Effect of (a): surfactant types, and (b): diluting solvents, on relative fluorescence intensity of the studied analytes at Dλ of 60 nm using AFH: 10 ng ml−1 and TDF: 100 ng ml−1.
Assessment of proposed spectrofluorometric method greenness using penalty points of Analytical Eco-scale.
| reagents | total penalty points [ |
|---|---|
| ethanol (10 ml/sample) | 1 × 1 = 1 |
| instrument | |
| energy | 0 (≤0.1 kWh per sample) |
| occupational hazard | 0 (no vapours) |
| waste | 3 (no treatment) |
| total penalty points | 4 |
| analytical Eco-scale total score | 96 |
Figure 5(a) GAPI for greenness assessment and (b) obtained AGREE graph for the proposed method.
Precision of the proposed method for the determination of AFH and TDF in their raw materials.
| sample concentration (ng. ml−1) | % founda (intra-day precision) | % founda (inter-day precision) | sample concentration (ng. ml−1) | % founda (intra-day precision) | % founda (inter-day precision) |
|---|---|---|---|---|---|
| AFH | TDF | ||||
| 40 | 101.35 | 99.08 | 20 | 101.01 | 98.5 |
| 98.57 | 100.34 | 100.78 | 100.78 | ||
| 98.06 | 101.86 | 100.78 | 101.69 | ||
| X′ ± s.d. | 99.31 ± 1.77 | 100.41 ± 1.39 | X′ ± s.d | 100.85 ± 0.13 | 100.30 ± 1.64 |
| % RSD | 1.78 | 1.39 | % RSD | 0.13 | 1.64 |
| % error | 1.03 | 0.80 | % error | 0.08 | 0.94 |
| 60 | 99.22 | 100.07 | 50 | 100.38 | 99.47 |
| 99.9 | 101.41 | 101.74 | 98.56 | ||
| 100.07 | 100.91 | 99.01 | 101.29 | ||
| X′ ± s.d. | 99.73 ± 0.45 | 100.79 ± 0.68 | X′ ± s.d | 100.36 ± 1.37 | 99.76 ± 1.39 |
| % RSD | 0.45 | 0.67 | % RSD | 1.36 | 1.39 |
| % error | 0.23 | 0.39 | % error | 0.79 | 0.80 |
| 80 | 101.06 | 100.59 | 80 | 99.14 | 98 |
| 100.33 | 101.34 | 100.85 | 100.28 | ||
| 100.84 | 101.47 | 101.42 | 101.99 | ||
| X′ ± s.d. | 100.74 ± 0.37 | 101.13 ± 0.48 | X′ ± s.d | 100.46 ± 1.19 | 100.06 ± 2.00 |
| % RSD | 0.37 | 0.47 | % RSD | 1.18 | 2.00 |
| % error | 0.21 | 0.27 | % error | 0.68 | 1.16 |
aAverage of three individual assays.